Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease ; volume:9 ; number:1 ; day:2 ; month:3 ; year:2023 ; pages:1-7 ; date:12.2023
npj Parkinson's Disease ; 9, Heft 1 (2.3.2023), 1-7, 12.2023
- Creator
-
Weber, Matthew A.
Sivakumar, Kartik
Tabakovic, Ervina E.
Oya, Mayu
Aldridge, Georgina M.
Zhang, Qiang
Simmering, Jacob E.
Narayanan, Nandakumar S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-023-00477-1
- URN
-
urn:nbn:de:101:1-2024011911273282727418
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.06.20242026, 7:12 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Weber, Matthew A.
- Sivakumar, Kartik
- Tabakovic, Ervina E.
- Oya, Mayu
- Aldridge, Georgina M.
- Zhang, Qiang
- Simmering, Jacob E.
- Narayanan, Nandakumar S.
- SpringerLink (Online service)
Other Objects (12)
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson’s disease
Urology Residency Directors' Awareness of Association between α-Adrenergic Antagonists and Floppy Iris Syndrome and Practice Patterns Regarding Prophylactic α-Adrenergic Antagonists
Parkinson
Parkinson
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Excitatory amino acid antagonists and Parkinson's disease [Reply to letter to the editor]
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson’s disease
Urology Residency Directors' Awareness of Association between α-Adrenergic Antagonists and Floppy Iris Syndrome and Practice Patterns Regarding Prophylactic α-Adrenergic Antagonists
Parkinson
Parkinson
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Excitatory amino acid antagonists and Parkinson's disease [Reply to letter to the editor]
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson’s disease
Urology Residency Directors' Awareness of Association between α-Adrenergic Antagonists and Floppy Iris Syndrome and Practice Patterns Regarding Prophylactic α-Adrenergic Antagonists
Parkinson
Parkinson
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Excitatory amino acid antagonists and Parkinson's disease [Reply to letter to the editor]
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease